Palvella Therapeutics (PVLA) FCF Margin (2016 - 2024)
Historic FCF Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2957.46%.
- Palvella Therapeutics' FCF Margin rose 13824000.0% to 2957.46% in Q4 2024 from the same period last year, while for Dec 2024 it was 8437.5%, marking a year-over-year increase of 84698300.0%. This contributed to the annual value of 2511.63% for FY2024, which is 25440400.0% up from last year.
- Per Palvella Therapeutics' latest filing, its FCF Margin stood at 2957.46% for Q4 2024, which was up 13824000.0% from 2079.25% recorded in Q1 2024.
- Palvella Therapeutics' 5-year FCF Margin high stood at 2957.46% for Q4 2024, and its period low was 2079.25% during Q1 2024.
- Over the past 5 years, Palvella Therapeutics' median FCF Margin value was 148.88% (recorded in 2021), while the average stood at 7.34%.
- Per our database at Business Quant, Palvella Therapeutics' FCF Margin skyrocketed by 17961000bps in 2023 and then tumbled by -15297900bps in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' FCF Margin stood at 745.6% in 2020, then soared by 82bps to 133.67% in 2021, then tumbled by -65bps to 221.04% in 2022, then soared by 813bps to 1575.06% in 2023, then surged by 88bps to 2957.46% in 2024.
- Its last three reported values are 2957.46% in Q4 2024, 2079.25% for Q1 2024, and 1575.06% during Q4 2023.